Ocimum Biosolutions' Biotracker awarded caBIG Bronze Compatibility Certification

Ocimum Biosolutions today announced that its specialty life science Laboratory Information Management System (LIMS), Biotracker™ has been awarded the prestigious caBIG® (cancer Biomedical Informatics Grid®) Bronze Compatibility Certification by the National Cancer Institute, an institute of the National Institutes of Health, U.S. Department of Health and Human Services.

The overarching goal of the caBIG® program is to develop a truly collaborative information network that accelerates the discovery of new approaches for the detection, diagnosis, treatment, and prevention of cancer, ultimately improving patient outcomes. This is done by enabling collaboration between researchers by providing an interoperable IT infrastructure that facilitates data sharing. caBIG® provides a set of compatibility guidelines, covering computational interfaces and the semantic description of a data system, that provides detailed guidance on how to build a software system that will interoperate within the caBIG® framework.

Being granted a Bronze Compatibility Certification guarantees that Biotracker™ LIMS is compliant to the caBIG® guidelines in each of four areas: (1) Programmatic access to data; (2) Use of controlled vocabularies; (3) Use and accessibility of data elements and metadata; and (4) Availability of a diagrammatic representation of the information model used.

“A critical problem facing basic and clinical researchers today is the explosion of data and how to effectively manage and share this data,” states Dr. Howard J. Rosenberg, Executive Director of LIMS at Ocimum Biosolutions. “By attaining caBIG® Bronze Compatibility, Ocimum’s Biotracker™ LIMS provides the infrastructure and interoperability that is so critically needed to promote knowledge sharing and ultimately translational medicine,” affirms Dr. Rosenberg.


 Ocimum Biosolutions


The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Novel Co-STAR cells show promise in targeting and eradicating cancer